BRAF+ mutations have been identified in approximately half of melanoma patients[1,2]

In BRAF V600+ melanoma patients

PrTAFINLAR® + PrMEKINIST®, as monotherapy or in combination, are indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

TAFINLAR® + MEKINIST®, in combination, are indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection.

Start with TAFINLAR® ⊕ MEKINIST®

Please consult the Product Monographs at **www.novartis.ca/tafinlarmonograph** and **www.novartis.ca/mekinistmonograph** for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monographs are also available through our medical department. To report an adverse event, please call **1-800-363-8883**.

References: 1. TAFINLAR® Product Monograph. Novartis Pharmaceuticals Canada Inc. December 11, 2019. **2.** MEKINIST® Product Monograph. Novartis Pharmaceuticals Canada Inc. December 6, 2019.

NOVARTIS

Novartis Pharmaceuticals Canada Inc.
Dorval, Québec H9S 1A9
www.novartis.ca
514.631.6775 514.631.1867

Printed in Canada
March/2020 – PRO/MTF/0071E

PAAB MEMBER OF INNOVATIVE MEDICINES CANADA

PrTafinlar® (dabrafenib mesylate) + PrMekinist® (trametinib)